Vitamin D immune cell therapy for progressive MS
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests a new treatment using your own immune cells trained with vitamin D to calm MS. It is for people with progressive MS who are not on other MS drugs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have a diagnosis of multiple sclerosis (MS) that is getting worse over time, not relapsing.
- Your MS symptoms are mild to moderate (you can walk with or without help).
- You have not had any MS relapses in the last 2 years.
- You are not currently taking any MS medication (like interferons, fingolimod, or ocrelizumab).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy called SYS6020 for people with multiple sclerosis that has not improved with standard treatments. The goal is to see if it can slow or stop the disease and improve symptoms.
This trial tests a new cell therapy called S103 for people with MS that isn't responding well to standard treatments. The therapy involves modifying immune cells in the lab and putting them back into your body to help control the disease.
This trial is testing a type of immunotherapy called CAR-T cells (made from your own immune cells) to see if it can help slow or stop progressive multiple sclerosis. It is a very early safety study, so only people with progressive MS who meet strict health criteria can join.
This study looks at how well different treatments, including bone marrow transplant, alemtuzumab, ocrelizumab, and ofatumumab, work for people with relapsing-remitting MS who have active disease. It will help doctors understand which therapy might slow disease progression best.
This early-stage trial tests a combination treatment—a CD20 antibody (which targets certain immune cells) paired with NK042 cell injection (a type of immune cell therapy)—for people with multiple sclerosis. The goal is to evaluate whether this combination is safe and may help slow disease progression.
This trial tests a new type of immune cell therapy (CAR T-cells) that targets CD19 and BCMA proteins on B cells. It is for people with certain neurological autoimmune diseases that have come back or not responded to standard treatments. The goal is to see if this therapy can help control the disease.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.